

Hong Kong Exchanges and Clearing Limited and the Stock Exchange of Hong Kong Limited takes no responsibility for the contents of this announcement, makes no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

WEGO 威高

山東威高集團醫用高分子製品股份有限公司

Shandong Weigao Group Medical Polymer Company Limited *

(a joint stock limited company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1066)

**COMPLETION OF DISCLOSEABLE TRANSACTION
DISPOSAL OF 50% EQUITY INTEREST IN
JWMS IN CONSIDERATION FOR
CASH, BIOSENSORS SHARES AND CONVERTIBLE NOTES**

Completion of the SPA took place on 3 October 2011.

Reference is made to announcement of Shandong Weigao Group Medical Polymer Company Limited (the “Company”) dated 11 June 2011 (the “Announcement”). Terms used in this announcement shall have the same meanings as those defined in the Announcement unless the context requires otherwise.

The board of the Company is pleased to announce that all the conditions precedent set out in the SPA have been satisfied and Completion took place on 3 October 2011. Upon Completion, Biosensors has satisfied the consideration by way of (i) as to S\$160.0 million (equivalent to approximately HK\$953.2 million) by way of cash ; (ii) as to S\$317.6 million (equivalent to approximately HK\$1,892.1 million) by way of issue of 260,000,000 Biosensors Shares credited as fully paid at S\$1.2215 per Biosensors Share; and (iii) as to US\$120,043,000 (equivalent to approximately HK\$934.7 million) by way of issue of Convertible Notes.

* For identification purpose only

Upon Completion, the Company will hold approximately 16.2% of the issued share capital of Biosensors as enlarged by the allotment and issue of the Consideration Shares and assuming exercise in full of the conversion rights attached to the Convertible Notes, the Company will hold approximately 21.6% of the issued share capital of Biosensor as enlarged by the allotment and issue of Consideration Shares and upon exercise in full of the conversion rights attached to the Convertible Notes. JWMS will become the wholly owned subsidiary of Biosensors upon Completion.

In this announcement, all amounts in S\$ are converted into HK\$ at the exchange rate of S\$1.00: HK\$5.9578, US\$ are converted into HK\$ at the exchange rate of US\$1.00: HK\$7.7863. The conversion rate is for the purpose of illustration only and does not constitute a representation that any amounts have been, would have been, or may be exchanged at the aforementioned or any other rates.

By Order of the Board
Shandong Weigao Group Medical Polymer Company Limited
Chen Xue Li
Chairman

3 October 2011
Shandong, the PRC

As at the date of this announcement, the Board comprises:

Mr. Zhang Hua Wei (*Executive Director*)

Mr. Miao Yan Guo (*Executive Director*)

Mr. Wang Yi (*Executive Director*)

Mr. Wang Zhi Fan (*Executive Director*)

Mr. Wu Chuan Ming (*Executive Director*)

Mr. Chen Xue Li (*Non-executive Director*)

Ms. Zhou Shu Hua (*Non-executive Director*)

Mr. Li Bing Yung (*Non-executive Director*)

Mr. Jean-Luc Butel (*Non-executive Director*)

Mr. Luan Jian Ping (*Independent non-executive Director*)

Mr. Li Jia Miao (*Independent non-executive Director*)

Mr. Lo Wai Hung (*Independent non-executive Director*)